Abstract Library

#4309 Head-to-head comparison of 18F-AIF-NOTA-octreotide and 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine neoplasms

Introduction: 18F-AIF-NOTA-octreotide (F-Oc) is a radiolabelled SSA emerging as a potential alternative to 68Ga-DOTATATE (Ga-DT) due to logistical advantages. Recent studies indicate that F-Oc has comparable diagnostic accuracy to Ga-DT in neuroendocrine neoplasm (NEN) and, in some cases, can identify a greater number of lesions.

Conference:

Presenting Author: Bel-Ange A

Authors: Ben-Haim S, Bel-Ange A, Chicheportichee A, Maimon O, Aburbeh G,

Keywords: 68Ga-DOTATATE, NEN, 18F-AIF-NOTA-octreotide,

#4168 BRCA gene mutations and NEN – Is it just random or a meaningful coincidence?

Introduction: A BRCA mutation denotes a genetic alteration found in either the BRCA1 or BRCA2 genes, both of which function as tumor suppressors. BRCA mutations are widely acknowledged for their link to breast and ovarian cancers, and rarely, to other malignancies such as the pancreas and prostate. Noteworthy, there have been limited reports associating BRCA mutations with NEN, and no possible co-relation to certain racial/ethnic populations has been reported to date.

Conference:

Presenting Author: Bel-Ange A

Authors: Bel-Ange A, Maimon O, Grozinsky-Glasberg S,

Keywords: BRCA gene mutation, NEN-neuroendocrine neoplasm,

#1293 The Role of Hepatic Intra-arterial Therapies in Metastatic Neuroendocrine Tumours (NETs): A Specialist Center Experience.

Introduction: Liver metastases are relatively common in patients with NETs, having a negative impact on prognosis. The options for selective liver metastases therapy are limited to catheter guided procedures: TACE, TAE or SIRT. Data regarding the effectiveness & safety of these procedures in different types of NETs is limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Grozinsky-Glasberg S, Klimov A, Salmon A, Besiso H, Maimon O,

Keywords: hepatic chemoembolization, SIRT, NETs, MTC,